The Beauty Health Company announced a collaboration with biotech company Organicell to co-create a first-to-market exosome booster that will address signs of aging and inflammation in the skin. The booster will leverage novel exosome technology based on regenerative medical therapies and, once developed, will be available as a customized treatment addition for Hydrafacial. Exosomes are small membrane vesicles, which are among the most productive and conducive to wound healing and countering inflammation.

These benefits will help treat the skin and address signs of aging when delivered as a booster through Hydrafacial's exceptional delivery system. The exosomes in Organicell's technology contain over 300 cytokines, chemokines and growth factors harvested under cGMP conditions that will allow Hydrafacial to put billions of exosomes in each booster vial. Within the booster, they will promote cellular communication, repair and regeneration to address signs of aging and inflammation like never before.

This collaboration marks a major advancement in Hydrafacial's booster strategy, which is centered around partnerships and co-creation. Hydrafacial has a lineup of 20 boosters, the majority co-created with fellow skincare brands such as Murad, ZO and JLo Beauty. Hydrafacial's co-creation model can deliver a booster in under six months, a fraction of the time typically required to develop a full skincare line.

This enables Hydrafacial to react rapidly to consumer trends, ensuring a constant flow of groundbreaking offerings that are directly addressing consumer needs. Hydrafacial's new exosome booster will be available early next year.